|
|
Volumn 343, Issue , 2011, Pages
|
|
GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ANTIDIABETIC AGENT;
ROSIGLITAZONE;
CONFLICT;
DRUG INDUSTRY;
GOVERNMENT;
LEGAL ASPECT;
MARKETING;
NOTE;
UNITED STATES;
DISSENT AND DISPUTES;
DRUG INDUSTRY;
HYPOGLYCEMIC AGENTS;
MARKETING;
THIAZOLIDINEDIONES;
UNITED STATES;
UNITED STATES GOVERNMENT AGENCIES;
|
|
EID: 84855164424
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.d7234 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
